Global Multivalent Vaccines Share Analysis 2025, Forecast To 2034
19 Mar, 2025
How Has the Multivalent Vaccines Market Evolved Historically and What is its Current Size?
The multivalent vaccines market has seen considerable growth due to a variety of factors.
• The market size for multivalent vaccines has experienced significant growth in the past few years. It is set to expand from $8.37 billion in 2024 to $9.2 billion in 2025, marking a compound annual growth rate (CAGR) of 10.0%.
The stimulating growth during the historic period can be credited to various factors including heightened public consciousness regarding vaccination, enhanced government backing, increased need for pediatric multivalent vaccines, escalating funds for vaccine research, and an upsurge in demand for multivalent vaccines.
What Does Future Hold for The Multivalent Vaccines Market By 2029?
The multivalent vaccines market is expected to maintain its strong growth trajectory in upcoming years.
• Expectations suggest that the multivalent vaccines market size is poised for robust expansion in the succeeding years, potentially reaching $13.32 billion by 2029 with a 9.7% compound annual growth rate (CAGR). This projected growth during the forecast period is ascribed to escalating rates of infectious diseases, swelling numbers of the elderly population, increased funding from government and private entities, a heightened emphasis on vaccine efficacy and safety, and an intensifying focus on therapeutic vaccines. Noteworthy trends anticipated throughout the forecast period encompass an increased inclination towards combination vaccines, the incorporation of digital health technologies, advancements in mRNA technology, the creation of tailored vaccines, and a surge in research pursuits.
What Are The Primary Growth Drivers In The Multivalent Vaccines Market?
The multivalent vaccines market is anticipated to grow due to the increasing occurrences of infectious diseases. These diseases, caused by bacteria, viruses, fungi, and other pathogens, are transmitted via direct contact or through unclean surfaces or air and water, and their severity may vary. The proliferation of infectious diseases is facilitated by worldwide travel, as it enables pathogens to swiftly traverse borders and afflict new groups of people. By targeting several strains of a pathogen in one dosage, multivalent vaccines offer comprehensive protection against infectious diseases, thereby eliminating the need for individual injections. This wide-range protection enhances herd immunity and reduces disease incidence, thus improving public health. For example, a report by TravelHealthPro, a UK Health Security Agency-backed website, stated that the UK had reported 2,004 cases of malaria in April 2024, an upsurge from the 1,369 imported cases in 2022. Consequently, the escalating instances of infectious diseases are fuelling the growth of the multivalent vaccines market.
What Is The Segmentation Of The Global Multivalent Vaccines Market?
The multivalent vaccinesmarket covered in this report is segmented –
1) By Type: Conjugate Vaccines, Inactivated And Subunit Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines
2) By Disease: Influenza, Pneumonia, Hepatitis, Meningitis, Rotavirus
3) By Route Of Administration: Oral, Injectable
4) By Age Group: Pediatrics, Adults, Geriatrics
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Conjugate Vaccines: Polysaccharide Conjugate Vaccines, Protein Conjugate Vaccines
2) By Inactivated And Subunit Vaccines: Inactivated Whole Virus Vaccines, Subunit Protein Vaccines, Virus-Like Particle Vaccines
3) By Live Attenuated Vaccines: Live Attenuated Bacterial Vaccines, Live Attenuated Viral Vaccines
4) By Toxoid Vaccines: Diphtheria Toxoid Vaccines, Tetanus Toxoid Vaccines
5) By Recombinant Vaccines: Recombinant Protein Vaccines, Recombinant DNA Vaccines
How Are Emerging Trends Reshaping The Dynamics Of The Multivalent Vaccines Market?
Leading businesses in the multivalent vaccines industry are concentrating their efforts on creating superior pentavalent vaccines to bolster overall public health results by providing more comprehensive protection with a single dose. The pentavalent vaccine, a type of multivalent vaccine, is designed to guard against five different pathogens or strains. This kind of multi-protection vaccine simplifies vaccination schedules and boosts overall vaccination coverage. For example, EasyFourPol, a groundbreaking fully liquid vaccine, was launched by Panacea Biotec Ltd., a biotech firm based in India, in December 2023. It safeguards against five severe diseases such as diphtheria, tetanus, pertussis, polio, and invasive infections caused by Haemophilus influenzae Type B. This ready-to-administer combination vaccine obviates the requirement for preparation by medical staff, promoting a smoother vaccination process. It provides equivalent protection to single-antigen vaccines, lessens the number of clinic visits required for children, and diminishes total immunization expenses. Furthermore, it maximizes vaccination efficiency while reducing the need for vials, syringes, and packaging thus minimizing environmental impact.
Who Are the Key Players In The Multivalent Vaccines Market?
Major companies operating in the multivalent vaccines market are:
• Pfizer Inc.
• Merck & Co. Inc.
• Sanofi SA
• AstraZeneca plc
• Abbott Laboratories
• Novartis AG
• GlaxoSmithKline plc
• Boehringer Ingelheim International GmbH
• Moderna Inc.
• BioNTech SE
• Zydus Lifesciences Limited
• CSL Seqirus
• Sinovac Biotech Ltd.
• GC Biopharma corp.
• Emergent BioSolutions Inc.
• Serum Institute of India Pvt. Ltd.
• Indian Immunologicals Ltd.
• Bavarian Nordic
• Panacea Biotec Ltd.
• WestVac Biopharma Co. Ltd.
• VBI Vaccines Inc.
What Are The Regional Insights Into The Multivalent Vaccines Market?
North America was the largest region in the multivalent vaccines market in 2024. The regions covered in the multivalent vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.